Diabetes
Conditions
Interventions
Once-daily administration of liraglutide (morning or evening)
Once-daily administration of insulin glargine (before breakfast)
Sponsors
University of Yamanashi, Faculty of Medicine Department of Internal Medicine III
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. HbA1c(NGSP): 6.5%<= and <9.0% 2. GAD antibody positive (>=1.5U/mL) and fasting s-CPR >=1.0ng/mL 3. Duration of diabetes: 6 months<= and <=10 years 4. Age: 20<= and <80 years old 5. Patients who can washout OADs (sulfonylurea, biguanide, alpha-glucosidase inhibitor, gulinide, pioglitazone, DPP-4 inhibitor) or insulin therapy more than 1-month (1-week in case of insulin) before the entry. 6. Patients without history of liraglutide, exenatide or lixisenatide treatment
Exclusion criteria
Exclusion criteria: 1. Ketosis 2. Pregnant, or intention of becoming pregnant 3. Patients who has serious complication or concurrent disease 4. Any other condition which the investigator feels would interfere with the participation.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Change in s-CPR after oral glucose tolerance test | — |
Secondary
| Measure | Time frame |
|---|---|
| 1. Percentage of withdrawn patients whose HbA1c are over 9.4%(NGSP) at two consecutive times measurements and the term until withdrawal. 2. Change in blood glucose level after oral glucose tolerance test every 6-month. 3. Change in HbA1c 4. Change in fasting plasma glucose 5. Change in fasting s-CPR 6. Change in circadian variability of blood-glucose 7. Change in weight 8. Change in blood pressure. 9. Change in islet autoantibodies (GAD antibody, IA-2 antibody, Insulin antibody, ZnT8 antibody) | — |
Countries
Japan
Contacts
Public ContactTetsuro Kobayashi
University of Yamanashi, Faculty of Medicine Department of Internal Medicine III
Outcome results
None listed